Pacher Pál, Gao Bin
Laboratory of Physiological Studies, National Institutes of Health/NIAAA, 5625 Fishers Lane, MSC-9413, Bethesda, Maryland 20892-9413, USA.
Am J Physiol Gastrointest Liver Physiol. 2008 Apr;294(4):G850-4. doi: 10.1152/ajpgi.00523.2007. Epub 2008 Jan 31.
Recent studies have implicated dysregulation of the endocannabinoid system in various liver diseases and their complications (e.g., hepatitis, fibrosis, cirrhosis, cirrhotic cardiomyopathy, and ischemia-reperfusion), and demonstrated that its modulation by either cannabinoid 2 (CB(2)) receptor agonists or CB(1) antagonists may be of significant therapeutic benefits. This review is aimed to focus on the triggers and sources of endocannabinoids during liver inflammation and on the novel role of CB(2) receptors in the interplay between the activated endothelium and various inflammatory cells (leukocytes, lymphocytes, etc.), which play pivotal role in the early development and progression of inflammatory and other liver diseases.
最近的研究表明，内源性大麻素系统失调与各种肝脏疾病及其并发症（如肝炎、纤维化、肝硬化、肝硬化性心肌病和缺血再灌注）有关，并证明大麻素2（CB(2)）受体激动剂或CB(1)拮抗剂对其进行调节可能具有显著的治疗益处。本综述旨在关注肝脏炎症期间内源性大麻素的触发因素和来源，以及CB(2)受体在活化内皮细胞与各种炎症细胞（白细胞、淋巴细胞等）相互作用中的新作用，这些炎症细胞在炎症性和其他肝脏疾病的早期发展和进展中起关键作用。
